22:58 , Oct 11, 2018 |  BC Week In Review  |  Clinical News

Celgene discontinues Phase I of anti-CD47 antibody in AML/MDS

Celgene Corp. (NASDAQ:CELG) discontinued a Phase I trial evaluating CC-90002 (INBRX-103) to treat acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). According to ClinicalTrials.gov, the company terminated the trial because preliminary data "did not...
20:03 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest inhibiting CD47 could help treat pediatric brain tumors. In orthotopic xenograft mouse models of five subtypes of pediatric brain cancer -- medulloblastoma, atypical teratoid rhabdoid tumor, primitive neuroectodermal tumor,...
07:00 , Aug 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD47; stem cell factor receptor tyrosine kinase (c-Kit; KIT; CD117)

Cardiovascular disease INDICATION: Atherosclerosis; stem cell transplant Patient sample and mouse studies suggest CD47 inhibitors could help treat atherosclerosis and condition patients for hematopoietic stem cell transplants (HSCTs). In carotid artery samples from atherosclerosis patients,...
07:00 , Aug 25, 2016 |  BC Innovations  |  Targets & Mechanisms

Forty Seven and counting

With companies lining up to block CD47 for cancer, the cell surface protein is emerging as one of the top new targets in oncology. But the list of suitors could be about to get a...
07:00 , Aug 22, 2016 |  BioCentury  |  Finance

Tioma's broad basket

Tioma Therapeutics Inc. will avoid putting its eggs in one basket and use last week's tranched $86 million series A round to launch a broad clinical program targeting CD47 . President and CEO John Donovan...
07:00 , Jul 25, 2016 |  BioCentury  |  Emerging Company Profile

Targeted phagocytosis

Alexo Therapeutics Inc. is developing variants of signal regulatory protein alpha that antagonize CD47 to increase macrophage phagocytosis induced by anticancer antibodies. Using the variants alongside antibody therapeutics could avoid on-target phagocytosis of healthy cells...